DRUG
Bright Minds Biosciences Inc. [DRUG] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
DRUG Stock Summary
Top 10 Correlated ETFs
DRUG
Top 10 Correlated Stocks
DRUG
In the News
DRUG Financial details
Company Rating
-
Market Cap
5.49M
Income
-6.81M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
-
Optionable
No
Shortable
Yes
Earnings
27 May 2024
P/E
-1.31
Forward P/E
-
PEG
0.19
P/S
-
P/B
1.51
P/C
-
P/FCF
-1.7
Quick Ratio
24.16
Current Ratio
24.26
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.8
EPS next Y
-
EPS next Q
-
EPS this Y
-67.8%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
7.32%
-
-
-
-
SMA20
-3.8%
SMA50
-11.05%
SMA100
3055.45%
Inst Own
-
Inst Trans
-
ROA
-110%
ROE
-88%
ROC
-1.1%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.09-6.44
52W High
+475%
52W Low
+3350%
RSI
44.96
Rel Volume
0.99
Avg Volume
26.11K
Volume
25.9K
Perf Week
2.47%
Perf Month
6.88%
Perf Quarter
2660%
Perf Half Y
2926.32%
-
-
-
-
Beta
1.527
-
-
Volatility
1.51%, 4.68%
Prev Close
-3.9%
Price
34.5
Change
-0.98%
Company Profile
- Volume Average 26.11K
- Market Capitalization 5.49M
- CEO Mr. Ian McDonald
- Headquarters Vancouver,BC,CA
- IPO Date 2021-03-22
-
Website
https://brightmindsbio.com 
Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.
